Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092143661> ?p ?o ?g. }
- W2092143661 endingPage "147" @default.
- W2092143661 startingPage "139" @default.
- W2092143661 abstract "Fifteen patients with previously untreated chronic lymphocytic leukemia (CLL) were treated with oral fludarabine. Toxicities were mainly hematologic, and the response rate was 80%. To assess the effect of fludarabine on the transcription factor STAT1, blood samples obtained on study entry were treated in vitro with fludarabine for 24 h, and the majority of samples displayed an expected decrease in STAT1. To determine whether similar changes occurred in vivo, we developed a flow cytometric assay to quantitate STAT1 levels. On completion of fludarabine cycle 1, CLL cells showed increased STAT1 in the majority of patients, in contrast to the in vitro findings. This may reflect a survival advantage for cells that express high levels of STAT1. In conclusion, oral fludarabine is highly active and merits further investigation in previously untreated patients with CLL. Larger studies are indicated to determine optimal timing of STAT1 assessment, and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy." @default.
- W2092143661 created "2016-06-24" @default.
- W2092143661 creator A5003947352 @default.
- W2092143661 creator A5015100500 @default.
- W2092143661 creator A5024967597 @default.
- W2092143661 creator A5032906131 @default.
- W2092143661 creator A5037942629 @default.
- W2092143661 creator A5038526399 @default.
- W2092143661 creator A5046785733 @default.
- W2092143661 creator A5047880272 @default.
- W2092143661 creator A5049433553 @default.
- W2092143661 creator A5067154165 @default.
- W2092143661 creator A5073116324 @default.
- W2092143661 creator A5077510009 @default.
- W2092143661 creator A5077671733 @default.
- W2092143661 creator A5081876895 @default.
- W2092143661 date "2004-02-01" @default.
- W2092143661 modified "2023-09-23" @default.
- W2092143661 title "Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo" @default.
- W2092143661 cites W1243376384 @default.
- W2092143661 cites W1524269393 @default.
- W2092143661 cites W1702064501 @default.
- W2092143661 cites W1782483823 @default.
- W2092143661 cites W1826504911 @default.
- W2092143661 cites W1905059524 @default.
- W2092143661 cites W1930759119 @default.
- W2092143661 cites W1939111644 @default.
- W2092143661 cites W1976251413 @default.
- W2092143661 cites W1984257462 @default.
- W2092143661 cites W2013691481 @default.
- W2092143661 cites W2065349428 @default.
- W2092143661 cites W2080951919 @default.
- W2092143661 cites W2086637735 @default.
- W2092143661 cites W2088591622 @default.
- W2092143661 cites W2090975649 @default.
- W2092143661 cites W2100200868 @default.
- W2092143661 cites W2117291755 @default.
- W2092143661 cites W2156131696 @default.
- W2092143661 cites W2161926682 @default.
- W2092143661 cites W2232484018 @default.
- W2092143661 cites W2318933236 @default.
- W2092143661 cites W2326175431 @default.
- W2092143661 cites W3041047318 @default.
- W2092143661 cites W4249092807 @default.
- W2092143661 cites W60865865 @default.
- W2092143661 cites W899734449 @default.
- W2092143661 doi "https://doi.org/10.1016/s0145-2126(03)00213-3" @default.
- W2092143661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14654078" @default.
- W2092143661 hasPublicationYear "2004" @default.
- W2092143661 type Work @default.
- W2092143661 sameAs 2092143661 @default.
- W2092143661 citedByCount "19" @default.
- W2092143661 countsByYear W20921436612012 @default.
- W2092143661 countsByYear W20921436612013 @default.
- W2092143661 countsByYear W20921436612020 @default.
- W2092143661 countsByYear W20921436612021 @default.
- W2092143661 countsByYear W20921436612023 @default.
- W2092143661 crossrefType "journal-article" @default.
- W2092143661 hasAuthorship W2092143661A5003947352 @default.
- W2092143661 hasAuthorship W2092143661A5015100500 @default.
- W2092143661 hasAuthorship W2092143661A5024967597 @default.
- W2092143661 hasAuthorship W2092143661A5032906131 @default.
- W2092143661 hasAuthorship W2092143661A5037942629 @default.
- W2092143661 hasAuthorship W2092143661A5038526399 @default.
- W2092143661 hasAuthorship W2092143661A5046785733 @default.
- W2092143661 hasAuthorship W2092143661A5047880272 @default.
- W2092143661 hasAuthorship W2092143661A5049433553 @default.
- W2092143661 hasAuthorship W2092143661A5067154165 @default.
- W2092143661 hasAuthorship W2092143661A5073116324 @default.
- W2092143661 hasAuthorship W2092143661A5077510009 @default.
- W2092143661 hasAuthorship W2092143661A5077671733 @default.
- W2092143661 hasAuthorship W2092143661A5081876895 @default.
- W2092143661 hasConcept C109246011 @default.
- W2092143661 hasConcept C126322002 @default.
- W2092143661 hasConcept C143998085 @default.
- W2092143661 hasConcept C150903083 @default.
- W2092143661 hasConcept C181199279 @default.
- W2092143661 hasConcept C202751555 @default.
- W2092143661 hasConcept C203014093 @default.
- W2092143661 hasConcept C207001950 @default.
- W2092143661 hasConcept C2776178377 @default.
- W2092143661 hasConcept C2776476023 @default.
- W2092143661 hasConcept C2776694085 @default.
- W2092143661 hasConcept C2776755627 @default.
- W2092143661 hasConcept C2777003663 @default.
- W2092143661 hasConcept C2777938653 @default.
- W2092143661 hasConcept C2778461978 @default.
- W2092143661 hasConcept C2779263901 @default.
- W2092143661 hasConcept C553184892 @default.
- W2092143661 hasConcept C55493867 @default.
- W2092143661 hasConcept C71924100 @default.
- W2092143661 hasConcept C86803240 @default.
- W2092143661 hasConcept C90924648 @default.
- W2092143661 hasConceptScore W2092143661C109246011 @default.
- W2092143661 hasConceptScore W2092143661C126322002 @default.
- W2092143661 hasConceptScore W2092143661C143998085 @default.
- W2092143661 hasConceptScore W2092143661C150903083 @default.
- W2092143661 hasConceptScore W2092143661C181199279 @default.